Anidulafungin: An evidence-based review of its use in invasive fungal infections

Susan L. Davis, Jose Antonio Vazquez

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Anidulafungin is a new echinocandin antifungal agent with indications for use in esophageal candidiasis and candidemia. The mortality and morbidity associated with fungal infections in healthcare facilities necessitates the development of new treatment options for these diseases. Aims: This review assesses the pharmacology and evidence for the use of anidulafungin in the treatment of serious fungal infections. Evidence review: There is substantial evidence that anidulafungin is a potent antifungal agent with activity against a broad range of fungal species. Likewise, evidence supports that anidulafungin is a well-tolerated antifungal agent. Clinical studies provide sufficient evidence for regulatory approval for esophageal candidiasis and candidemia, and limited evidence suggests that anidulafungin may be superior to fluconazole for candidemia and invasive candidiasis. The introduction of anidulafungin into clinical practice adds a third option for therapy in the echinocandin class. Research into its efficacy in other fungal infections is ongoing, and further studies into the impact of anidulafungin on economic outcomes will be beneficial. Place in therapy: Current evidence supports the use of anidulafungin in the management of candidemia, esophageal candidiasis, and invasive candidiasis, as demonstrated by the successful results in large multicenter clinical trials.

Original languageEnglish (US)
Pages (from-to)241-249
Number of pages9
JournalCore Evidence
Volume2
Issue number4
StatePublished - Oct 9 2008

Fingerprint

anidulafungin
Candidemia
Mycoses
Candidiasis
Antifungal Agents
Invasive Candidiasis
Echinocandins
Invasive Fungal Infections
Fluconazole
Multicenter Studies

Keywords

  • Anidulafungin
  • Candidemia
  • Candidiasis
  • Echinocandins
  • Evidence
  • Review
  • Treatment

ASJC Scopus subject areas

  • Reviews and References, Medical
  • Pharmacology

Cite this

Anidulafungin : An evidence-based review of its use in invasive fungal infections. / Davis, Susan L.; Vazquez, Jose Antonio.

In: Core Evidence, Vol. 2, No. 4, 09.10.2008, p. 241-249.

Research output: Contribution to journalReview article

@article{f2b6e0651d1f48c68d81573345d8274b,
title = "Anidulafungin: An evidence-based review of its use in invasive fungal infections",
abstract = "Introduction: Anidulafungin is a new echinocandin antifungal agent with indications for use in esophageal candidiasis and candidemia. The mortality and morbidity associated with fungal infections in healthcare facilities necessitates the development of new treatment options for these diseases. Aims: This review assesses the pharmacology and evidence for the use of anidulafungin in the treatment of serious fungal infections. Evidence review: There is substantial evidence that anidulafungin is a potent antifungal agent with activity against a broad range of fungal species. Likewise, evidence supports that anidulafungin is a well-tolerated antifungal agent. Clinical studies provide sufficient evidence for regulatory approval for esophageal candidiasis and candidemia, and limited evidence suggests that anidulafungin may be superior to fluconazole for candidemia and invasive candidiasis. The introduction of anidulafungin into clinical practice adds a third option for therapy in the echinocandin class. Research into its efficacy in other fungal infections is ongoing, and further studies into the impact of anidulafungin on economic outcomes will be beneficial. Place in therapy: Current evidence supports the use of anidulafungin in the management of candidemia, esophageal candidiasis, and invasive candidiasis, as demonstrated by the successful results in large multicenter clinical trials.",
keywords = "Anidulafungin, Candidemia, Candidiasis, Echinocandins, Evidence, Review, Treatment",
author = "Davis, {Susan L.} and Vazquez, {Jose Antonio}",
year = "2008",
month = "10",
day = "9",
language = "English (US)",
volume = "2",
pages = "241--249",
journal = "Core Evidence",
issn = "1555-1741",
publisher = "Dove Medical Press Ltd.",
number = "4",

}

TY - JOUR

T1 - Anidulafungin

T2 - An evidence-based review of its use in invasive fungal infections

AU - Davis, Susan L.

AU - Vazquez, Jose Antonio

PY - 2008/10/9

Y1 - 2008/10/9

N2 - Introduction: Anidulafungin is a new echinocandin antifungal agent with indications for use in esophageal candidiasis and candidemia. The mortality and morbidity associated with fungal infections in healthcare facilities necessitates the development of new treatment options for these diseases. Aims: This review assesses the pharmacology and evidence for the use of anidulafungin in the treatment of serious fungal infections. Evidence review: There is substantial evidence that anidulafungin is a potent antifungal agent with activity against a broad range of fungal species. Likewise, evidence supports that anidulafungin is a well-tolerated antifungal agent. Clinical studies provide sufficient evidence for regulatory approval for esophageal candidiasis and candidemia, and limited evidence suggests that anidulafungin may be superior to fluconazole for candidemia and invasive candidiasis. The introduction of anidulafungin into clinical practice adds a third option for therapy in the echinocandin class. Research into its efficacy in other fungal infections is ongoing, and further studies into the impact of anidulafungin on economic outcomes will be beneficial. Place in therapy: Current evidence supports the use of anidulafungin in the management of candidemia, esophageal candidiasis, and invasive candidiasis, as demonstrated by the successful results in large multicenter clinical trials.

AB - Introduction: Anidulafungin is a new echinocandin antifungal agent with indications for use in esophageal candidiasis and candidemia. The mortality and morbidity associated with fungal infections in healthcare facilities necessitates the development of new treatment options for these diseases. Aims: This review assesses the pharmacology and evidence for the use of anidulafungin in the treatment of serious fungal infections. Evidence review: There is substantial evidence that anidulafungin is a potent antifungal agent with activity against a broad range of fungal species. Likewise, evidence supports that anidulafungin is a well-tolerated antifungal agent. Clinical studies provide sufficient evidence for regulatory approval for esophageal candidiasis and candidemia, and limited evidence suggests that anidulafungin may be superior to fluconazole for candidemia and invasive candidiasis. The introduction of anidulafungin into clinical practice adds a third option for therapy in the echinocandin class. Research into its efficacy in other fungal infections is ongoing, and further studies into the impact of anidulafungin on economic outcomes will be beneficial. Place in therapy: Current evidence supports the use of anidulafungin in the management of candidemia, esophageal candidiasis, and invasive candidiasis, as demonstrated by the successful results in large multicenter clinical trials.

KW - Anidulafungin

KW - Candidemia

KW - Candidiasis

KW - Echinocandins

KW - Evidence

KW - Review

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=54749115204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54749115204&partnerID=8YFLogxK

M3 - Review article

C2 - 21221189

AN - SCOPUS:54749115204

VL - 2

SP - 241

EP - 249

JO - Core Evidence

JF - Core Evidence

SN - 1555-1741

IS - 4

ER -